

# Granules India Q4 net profit at ₹24 cr

TRUSHNA UDGIRKAR

Hyderabad

PHARMACEUTICAL products maker Granules India has posted consolidated sales of Rs 317.47 crore for the fourth quarter, with the total sales for the complete year at Rs 1,095.86 crore. The total income last year stood at Rs 764.37 crore.

The net profit of the firm stood at Rs 23.62 crore for Q4 FY14 against Rs 12.41 crore in the year-ago period. For the complete year, it stood at Rs 75.23 crore versus Rs 32.56 crore last year.

The growth was driven by a strong performance across all facilities including their Chinese joint venture. The primary growth driver in FY14 was led by Granules' commercialisation of its pharmaceutical formulation intermediates and finished dosage expansion at the Gagillapur facility.

The increased capacity utilisation shifted the prod-

uct mix more towards finished dosages along with a focus on operational excellence. "Additionally, the API (active pharmaceutical ingredients) units also increased capacity through debottlenecking which drove profitability," the firm said.

On a standalone basis, the finished dosage business contributed the largest share of revenue at 35 per cent while PFI and API amounted to 33 per cent and 32 per cent respectively. "In addition to growing our business, we have been looking at opportunities to diversify our sales by leveraging our efficient manufacturing. In the short-to-midterm, we will focus on selling APIs from the Auctus portfolio to customers in the regulated markets. Over the long term, we will add value by offering finished dosages from select APIs in the same portfolio," MD Krishna Prasad said.

trushnaudgirkar@mydigitalfc.com

Company